Alvotech Reports First Net Profit Since Inception, But Faces Adverse ICFR Opinion and FDA Delays for Key Biosimilars

summarizeSummary

Alvotech reported its first net profit in 2025, but the annual report also revealed an adverse auditor opinion on internal controls and FDA delays for three biosimilar candidates due to manufacturing deficiencies.

check_boxKey Events

• Achieves First Net Profit Since Inception

  Alvotech reported a net profit of $27.9 million for the year ended December 31, 2025, a significant turnaround from net losses of $231.9 million in 2024 and $551.7 million in 2023. Total revenue increased to $586.3 million in 2025, driven by growth in product sales and license/milestone payments.

• Adverse Opinion on Internal Controls Over Financial Reporting (ICFR)

  The company's independent registered public accounting firm issued an adverse opinion on the effectiveness of Alvotech's internal control over financial reporting as of December 31, 2025, citing material weaknesses in control environment, control activities, information and communication, and the deferred tax asset process.

• FDA Delays for Three Biosimilar Candidates

  Alvotech received Complete Response Letters (CRLs) from the FDA in late 2025 for its Biologics License Applications (BLAs) for AVT03 (denosumab), AVT05 (golimumab), and AVT06 (aflibercept). The CRLs cited deficiencies related to the Reykjavik manufacturing facility, delaying U.S. market entry for these products.

• Derecognition of Deferred Tax Assets

  The company derecognized $130.0 million of previously recognized deferred tax assets on accumulated tax losses in Iceland, as management determined it is no longer probable that sufficient future taxable profits will be available to fully utilize these losses.

auto_awesomeAnalysis

This annual report presents a mixed financial picture for Alvotech. While the company achieved its first net profit of $27.9 million in 2025 after years of losses and saw significant revenue growth, it also disclosed critical operational and compliance challenges. The auditor issued an adverse opinion on the company's internal control over financial reporting (ICFR) due to identified material weaknesses, which is a severe red flag for investors regarding financial reporting reliability. Furthermore, the FDA issued Complete Response Letters for three key biosimilar candidates (AVT03, AVT05, AVT06) due to manufacturing facility deficiencies, delaying their entry into the lucrative U.S. market. The derecognition of $130 million in deferred tax assets also signals a less optimistic long-term profitability outlook in Iceland. Investors should monitor the company's remediation efforts for ICFR and the progress of resubmissions to the FDA, as these issues could continue to impact future performance and investor confidence, especially with the stock trading near 52-week lows.